A Retrospective Clinical Study of 188 Consecutive Patients to Examine the Effectiveness of a Biologically Active Cryopreserved Human Skin Allograft (TheraSkin ®) on the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers

Abstract

A biologically active human skin allograft, currently distributed under the brand name TheraSkin^®, was examined for safety and efficacy in the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs). The objective was to determine if TheraSkin could serve as a safe and effective alternative to bioengineered skin substitutes such as Apligraf^® and Dermagraft^®. The authors conducted a retrospective study of 214 consecutive patients seen at the Inova Wound Center (Mt Vernon, Virginia), with either a DFU or a VLU. After excluding patients who did not meet the study criteria, the final eligible cohort consisted of 188 subjects, with 134 VLUs and 54 DFUs. Multivariate logistic regression was used to evaluate the relationship between baseline wound size and the proportion of healed wounds after 12 and 20 weeks from initial allograft application. The authors found that by the 12th week, DFUs closed 60.38% of the time and VLUs closed 60.77% of the time. After 20 weeks, the number of closed DFUs increased to 74.1% and the number of VLUs increased to 74.6%. The mean wound size in the DFU group was 6.2 cm² (±11.8) and 11.8 cm² (±22.5) in the VLU group. The mean number of TheraSkin allografts required ranged from 1 to 8, with an average of 2.03 (±1.47) at the 12-week point and an average of 3.23 (±2.77) at the 20-week point. Multivariate logistic regression was used to calculate the odds of wound healing by week 12 and week 20 in each group. The authors also analyzed adverse events and found TheraSkin to be noncontributory to any adverse events, verifying the safety of TheraSkin in this study population. In this study, TheraSkin has been shown to be highly effective for the treatment of both VLUs and DFUs with an acceptable safety profile.

Level of Evidence: Therapeutic, Level IV

Keywords

diabetes comorbid conditions distal wound healing wound care

Get full access to this article

View all access options for this article.

References

Sheehan P. , Jones P. , Caselli A. , Giurini JM , Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26:1879-1882.

Boulton AJ , Kirsner RS , Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med. 2004;352:48-55.

Steed DL , Attinger C. , Colaizzi T. , et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen. 2006;4: 680-692.

Armstrong D. , Granick MS , Marston WA , Phillips TJ , Sheehan P. A regimen to optimize the results of a living dermal substitute for healing diabetic foot ulcers. US Endocr Rev. 2007;Spring:60-66.

Veves A. , Falanga V. , Armstrong DG , Sabolinski ML Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multi-center clinical trial. Diabetes Care. 2001;24: 290-295.

Marston WA , Hanft J. , Norwood P. , Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26: 1701-1705.

Kirsner RS , Falanga V. Techniques of split-thickness skin grafting for lower extremity ulcerations . J Dermatol Surg Oncol. 1993;19:779-783.

Cornwell KG , Landsman A. , James KS Extracellular matrix biomaterials for soft tissue repair. Clin Podiatr Med Surg. 2009;26:507-523.

Eckes B. , Nischt R. , Krieg T. Cell-matrix interactions in dermal repair and scarring. Fibrogenesis Tissue Repair. 2010;3:4.

10.

Tran KT , Griffith L. , Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen. 2004;12:262-268.

11.

Lin Q. , Rosines E. , Clagett J. , Taylor BM Independent study funded by Skin and Wound Allograft Institute, a subsidiary of LifeNet Heatlh, Virginia Beach, VA. Study conducted at Albany Medical Center and the University of Maryland, Institute of Human, January 2010.

12.

Taylor BM Independent study funded by Skin and Wound Allograft Institute, a subsidiary of LifeNet Heatlh, Virginia Beach, VA. Study conducted at University of Maryland, March 2010.

13.

Spence RJ , Wong L. The enhancement of wound healing with human skin allograft. Surg Clin North Am. 1997;77:731-745.

14.

Margolis DJ , Kantor J. , Berlin JA Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care. 1999;22:692-695.

15.

Kantor J. , Margolis DJ Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg. 2001;27:347-351.

16.

Steinberg JS , Edmonds M. , Hurley DP Jr , King WN Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers. J Am Podiatr Med Assoc. 2010;100:73-77.

17.

Cardinal M. , Eisenbud D. , Zelen C. Successful healing in a consecutive series of diabetic foot ulcers treated with Dermagraft. Paper presented at: Diabetic Global Foot Conference; March 13-15, 2008.

18.

Omar AA , Mavor AID , Jones AM , Homer-Vanniasinkam S. Treatment of venous leg ulcers with Dermagraft. Eur J Vasc Endovasc Surg. 2004;27:666-672.

19.

Falanga V. , Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen . 1999;7: 201-207.

20.

Falanga V. , Margolis D. , Alvarez O. , et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch Dermatol . 1998;134:293-300.

21.

Falanga V. Wound healing and its impairment in the diabetic foot. Lancet . 2005;355:1736-1743.